SCHEMBL1049486

SCHEMBL1049486

CC(C)(CO)CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 19/20 0.81
ROCK2 O75116 18/20 0.81
PRKACA P17612 18/20 0.81
CDK2 P24941 17/20 0.81
HIPK2 Q9H2X6 17/20 0.81
PIM1 P11309 16/20 0.81
CLK4 Q9HAZ1 13/20 0.81
MAP4K4 O95819 13/20 0.81
CDK7 P50613 11/20 0.81
CDK9 P50750 11/20 0.81
DYRK1A Q13627 11/20 0.81
CLK2 P49760 10/20 0.81
CDK5 Q00535 10/20 0.81
STK17A Q9UEE5 10/20 0.81
DAPK3 O43293 9/20 0.81
PRKX P51817 9/20 0.81
PKN2 Q16513 9/20 0.81
MELK Q14680 8/20 0.81
PRKD3 O94806 8/20 0.81
PAK4 O96013 8/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1046787 0.90 CDC7 (1.00) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1044472 0.90 CDC7 (1.00) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1042644 0.89 CDC7 (0.84) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1048268 0.88 CDC7 (1.00) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1044210 0.88 ROCK2 (0.79) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1045415 0.88 ROCK2 (0.75) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1046335 0.86 ROCK2 (0.76) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1045430 0.85 CDC7 (1.00) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1042785 0.84 CDC7 (1.00) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1045439 0.84 CDC7 (0.69) CDC7ROCK2PRKACACDK2HIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP claimed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US claimed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US claimed
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP disclosed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US disclosed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885ROCK2 373/4885PRKACA 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.